TME Pharma TME Pharma (formerly known as NOXXON Pharma) is a clinical-stage biopharmaceutical company that focuses on the development of proprietary therapeutics for the treatment of cancer. | AstraZeneca AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. | Telix Pharmaceuticals Telix Pharmaceuticals is a company developing molecularly targeted radiation products for cancer care. | ||
Founding Date | Founding Date N/A | Founding Date 1998 | Founding Date 1999 | Founding Date 2015 |
Type | Type Private | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Macclesfield, GB HQ | Locations Berlin, DE HQ | Locations Cambridge, GB HQ Alger, DZ Buenos Aires, AR Macquarie Park, AU Macquarie Park, AU North Ryde, AU Wien, AT see more | |
Employees | Employees 4300% increase | Employees 13 | Employees 89,900 | Employees 415 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 6.6 m | Valuation ($) 2.7 b | Valuation ($) 4.6 b |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $45.8b (FY, 2023) | Revenue (est.) $502.5m (FY, 2023) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $7.2b (FY, 2023) | Cost of goods $181.4m (FY, 2023) |
Gross profit | Gross profit N/A | Gross profit €17k (FY, 2023) | Gross profit $39.8b (FY, 2023) | Gross profit $321.3m (FY, 2023) |
Net income | Net income N/A | Net income (€6.7m) (FY, 2023) | Net income $6b (FY, 2023) | Net income $5.2m (FY, 2023) |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised $ 110.9m | Total funding raised $ 1b | Total funding raised N/A |